The Importance of Continuity of Operations Plans for Gene Therapy Manufacturers

By: James Zoshak The COVID-19 pandemic has added increased risk and uncertainty to gene therapy supply chains. To mitigate this risk, it is critical for biopharmaceutical manufacturers to properly maintain the documentation governing their continuity of operations. It’s complicated: Gene therapy products supply chains and manufacturing While many people working in the pharmaceutical industry can … Continued

1 of 1
Back to top
Powered by GlobalLink OneLink Software